Mironid Ltd. has announced an extension of its series A financing round to support its development of small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company will use the proceeds of the financing to advance its lead discovery program through IND-enabling studies.
Gain Therapeutics Inc. has received human research ethics committee (HREC) approval in Australia to initiate a phase I study of its lead drug candidate GT-02287 in development for GBA1-Parkinson’s disease. The study is expected to begin in the near term.
Researchers from the University of Oxford and Oxstem Ltd. have discovered small-molecule candidates with the ability to induce differentiation of acute myeloid leukemia (AML) cells.
Pancreatic ductal adenocarcinoma (PDAC) is an exocrine pancreatic cancer with a poor prognosis and limited treatment options. There is a strong demand for new treatment strategies to overcome these challenges.
Riana Therapeutics GmbH, a spin-off from Vetmeduni Vienna founded this year, has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC) to support its efforts to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).
At the recent ERS meeting, researchers from Hilung Inc. and Ube Corp. presented preclinical data for the novel lysophospholipid LPA1 receptor antagonist, HL-001, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Senescence of lung epithelial tissue translates into fibrinolysis reduction and loss of tissue repair, both drivers of pulmonary fibrotic diseases. Researchers from Tokushima University reported on the effect of ARV-825, a BRD4 degrader, as an antifibrotic agent in lung fibrosis.
RSS
